Remdesivir US$2,340 Treatment For Covid-19

Drugmaker Gilead Sciences announced its pricing plans for remdesivir, an antiviral COVID-19 drug candidate, saying the treatment will cost $520 per dose for U.S. private insurance companies and $390 per dose for the U.S. government.

For a majority of people who receive a five-day treatment of the drug using six vials (based on current patterns), the total charged to hospitals for patients with private insurance in the U.S. will be $3,120. For those under U.S. government health programs, the total will be $2,340 per patient.

The costs do not represent out-of-pocket costs with a patient using private insurance. That amount would depend on the type of plan they have.
Gilead originally developed remdesivir to treat patients with Ebola virus disease. In May, the Food and Drug Administration authorized the drug for emergency use to treat patients hospitalized with severe cases of COVID-19. Since then, the U.S. government has been distributing treatment courses of remdesivir that were donated by Gilead.